Background/Aim: For recurrent/metastatic squamous cell carcinoma of the head and neck
(R/M SCCHN), popular regimens containing platinum-based anticancer agents and immune …

Background/Aim: Prior immune-checkpoint inhibitors, weekly paclitaxel-cetuximab was one
of the few options for platinum-ineligible patients with recurrent/metastatic squamous cell …

6012 Background: Cetuximab and paclitaxel have shown to be active in SCCHN pts and
preclinical data has demonstrated a possible synergy for the combination. In a variety of …

Purpose: We sought to evaluate the efficacy and safety of the combination of cetuximab
(Cmab) and paclitaxel (PTX) in patients with squamous cell carcinoma of the head and neck …

Abstract Background B490 (EudraCT# 2011-002564-24) is a randomized, phase 2b,
noninferiority study investigating the efficacy and safety of first-line cetuximab plus cisplatin …

Simple Summary The purpose of the CET-MET trial was to find a new platinum-based
chemotherapy regimen in combination with cetuximab for relapsed or metastatic squamous …

INTRODUCTION: The addition of cetuximab to weekly paclitaxel has demonstrated high
efficacy in the first-line treatment of patients with recurrent/metastatic squamous cell …

Background The standard of care for first-line treatment of recurrent and/or metastatic
squamous cell carcinoma of the head and neck (R/M SCCHN) is combination treatment with …

Background Until the emergence of immune checkpoint inhibitors, the EXTREME regimen
comprising platinum-based chemotherapy plus cetuximab was the standard of care for …

Objectives Identify predictors of outcome in patients with recurrent/metastatic head and neck
squamous cell carcinoma (RMHNSCC) treated with weekly cetuximab and paclitaxel (CP) …